TXG:NSD-10x Genomics Inc (USD)

COMMON STOCK | Health Information Services | NSD

Last Closing Price

USD 104.00

Change

0.00 (0.00)%

Market Cap

USD 11.62B

Volume

2.04M

Avg Analyst Target

USD 201.67 (+93.91%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


10x Genomics Inc (TXG) Stock Analysis:
Based on the 10x Genomics Inc stock forecasts from 4 analysts, the average analyst target price for 10x Genomics Inc is USD 201.67 over the next 12 months. 10x Genomics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of 10x Genomics Inc is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, 10x Genomics Inc’s stock price was USD 104.00. 10x Genomics Inc’s stock price has changed by -23.72% over the past week, -39.45% over the past month and -42.12% over the last year.

About

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect ins ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CERN Cerner Corporation

N/A

USD26.94B 54.24 13.44
GDRX GoodRx Holdings Inc

N/A

USD10.71B 927.27 238.21
OMCL Omnicell Inc

N/A

USD7.23B 94.97 44.39
CHNG Change Healthcare Inc

N/A

USD6.41B N/A 13.94
INOV Inovalon Holdings Inc

N/A

USD6.37B 122.57 33.93
RCM R1 RCM Inc

N/A

USD5.60B 72.63 31.09
PINC Premier Inc

N/A

USD4.82B 18.60 11.24
HQY HealthEquity Inc

N/A

USD4.18B 789.30 27.55
PGNY Progyny Inc

N/A

USD3.91B 47.62 117.41
HMSY HMS Holdings Corp

N/A

USD3.29B 47.40 23.59

ETFs Containing TXG

Symbol Name Weight Mer Price(Change) Market Cap
IS3T:XETRA iShares IV Public Limited.. 0.00 % 0.30 %

+0.32 (+0.82%)

USD0.71B
QDVC:XETRA iShares IV Public Limited.. 0.00 % 0.20 %

+0.12 (+1.29%)

USD0.14B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.59 %

+0.15 (+1.90%)

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.18% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.18% 3% F 2% F
Trailing 12 Months  
Capital Gain -42.12% 32% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.12% 32% F 25% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 53.40% 77% C+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.40% 77% C+ 86% B
Risk Return Profile  
Volatility (Standard Deviation) 66.32% 29% F 25% F
Risk Adjusted Return 80.51% 77% C+ 89% B+
Market Capitalization 11.62B 97% A+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 19.48 13% F 6% F
Price / Cash Flow Ratio -53,316.36 100% A+ 99% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -56.03% 14% F 26% F
Return on Invested Capital -91.25% 6% F 9% F
Return on Assets -2.59% 44% F 38% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.15 46% F 27% F
Short Percent 3.95% 43% F 39% F
Beta 1.38 24% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.